期刊
ANTICANCER RESEARCH
卷 38, 期 7, 页码 4035-4039出版社
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.12692
关键词
Pancreatic cancer; locally advanced; neoadjuvant; gemcitabine; nab-paclitaxel
类别
Background/Aim: Combination nab-paclitaxel/gemcitabine (AG) is superior to gemcitabine in patients with metastatic pancreatic cancer (PC). There are limited data for AG in borderline resectable (BR) or locally advanced pancreatic cancer (LAPC). Herein, we report our experience with neoadjuvant AG for BR/LAPC in patients ineligible for FOLFIRINOX. Patients and Methods: This retrospective series, included patients with BR/LAPC who received AG as neoadjuvant therapy for 3-4 months followed by radiation, then re-evaluation for surgery. Results: Between 1012013-212018, 32 patients (22 BR, 10 LAPC) were treated with this approach. Median age was 70 years. Nine patients were converted to resectability by imaging; six had RO resections (19%), five (16%) achieved a partial response and 24 (75%) had stable disease. Conclusion: In this small series, the RO resection rate and response rate were 19% and 16% respectively. These data suggest that neoadjuvant AG may be an alternate option for patients ineligible for FOLFIRINOX.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据